Mr. Donald McCaffrey reports

RESVERLOGIX ANNOUNCES COMBINED RVX-208 FINDINGS FROM SUSTAIN & ASSURE PHASE 2B TRIALS

Resverlogix Corp. has released new information arising from its continuing analysis of data from both the SUSTAIN and ASSURE trials in atherosclerotic patients with high risk for recurrent events. This analysis, performed by an independent firm, focuses on the potential benefit of RVX-208, a first-in-class BET inhibitor, to impact major adverse cardiac events (MACE) over a short time period of six months.

When MACE data (n equals 499) from both SUSTAIN and ASSURE trials were combined, it demonstrated that treatment with RVX-208 lead to a significant reduction in MACE. RVX-208-treated patients (n equals 331) had less cumulative events of 6.74 per cent versus 15.09 per cent (p equals 0.02) in the placebo-treated group (n equals 168). Furthermore, in patients who had elevated CRP (C-reactive protein) over two milligrams per decilitre (n equals 283), the benefit of RVX-208 treatment of patients (n equals 179) appeared more striking with a cumulative event rate of 6.42 per cent versus 20.53 per cent (p equals 0.007) in the placebo group (n equals 104).

"Analysis of the ASSURE and SUSTAIN data arising from similar atherosclerotic patients with high risk of recurrent events provides important MACE information," stated Donald McCaffrey, president and chief executive officer of Resverlogix. "A reduction in MACE will be a critical factor for registration of RVX-208. This analysis provides important information that RVX-208 when used in high-risk atherosclerosis patients improves the most central measurement of all, the reduction of MACE in back-to back-trials," said Mr. McCaffrey.

"We are very excited to have this independent MACE analyses performed from the combined ASSURE and SUSTAIN trials to assess the RVX-208 impact on death, non-fatal myocardial infarct, hospitalizations from cardiac events and percutaneous invasive procedures or revascularizations," stated Dr. Jan Johansson, senior vice-president of medical affairs at Resverlogix. "This early data is valuable to have as it illustrates in a cumulative fashion that RVX-208 has the potential to really impact cardiac events in those patients who are at very high risk," Dr. Johansson added.

About MACE

Major adverse cardiac events refers to adverse events caused by disease processes generally affecting the coronary arteries. These may include what are termed hard events, such as deaths that are attributed to coronary artery disease and non-fatal myocardial infarctions, but also occasionally soft events such as angina or revascularizations for progressive coronary artery disease.

About RVX-208

RVX-208 is a first-in-class small molecule that inhibits BET bromodomains. RVX-208 functions by removing atherosclerotic plaque via reverse cholesterol transport (RCT), the natural process through which atherosclerotic plaque is transported out of the arteries and removed from the body by the liver. RVX-208 increases production of Apolipoprotein A-I (ApoA-I), the key building block of functional high-density lipoprotein (HDL) particles and the type required for RCT. These newly produced, functional HDL particles are flat and empty, and can efficiently remove plaque and stabilize or reverse atherosclerotic disease. Analysis of recent clinical trials data showed that RVX-208 significantly reduces coronary atherosclerosis and major adverse cardiac events in patients with CVD (cardiovascular disease) who have a low level of HDL and elevated CRP, a population with unmet medical need. ApoA-I may also exert beneficial effects in Alzheimer's disease and diabetes mellitus.

We seek Safe Harbor.